Wesley Burkett, MD | Authors

Articles

Pembrolizumab and Lenvatinib Approval Opens New Door in Endometrial Cancer Treatment

October 12, 2022

Wesley Burkett, MD, adiscusses his excitement for the approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.